Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In SituE. Shelley Hwang, Doreen M. Agnese, Terry Hyslop et al.|JAMA|2024Cited by 75
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemicKo Un Park, Alastair M. Thompson, Megan E. Gregory et al.|Breast Cancer Research and Treatment|2021Cited by 41
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In SituAnn H. Partridge, Kimberly Strickland, Terry Hyslop et al.|JAMA Oncology|2024Cited by 16
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19Isaac A. Klein, Ann H. Partridge, Hannah Freeman et al.|The Oncologist|2021Cited by 8
Abstract GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)Ann H. Partridge, Shelley Hwang, Terry Hyslop et al.|Clinical Cancer Research|2025Cited by 0